Table 1.
Baseline characteristics and demographics
| Durva | Durva + Ole | Durva + Mona | Durva + Danva | Total | |
|---|---|---|---|---|---|
| (n = 27) | (n = 21) | (n = 20) | (n = 16) | (N = 84) | |
| Median age (min, max) | 67 (51, 83) | 65 (52, 80) | 64.5 (54, 82) | 71.5 (56, 87) | 67.5 (51, 87) |
| Sex, n (%) | |||||
| Male | 14 (51.9) | 12 (57.1) | 14 (70.0) | 10 (62.5) | 50 (59.5) |
| Female | 13 (48.1) | 9 (42.9) | 6 (30.0) | 6 (37.5) | 34 (40.5) |
| ECOG PS a , n (%) | |||||
| 0 | 19 (73.1) | 12 (57.1) | 12 (60.0) | 10 (62.5) | 53 (63.1) |
| 1 | 7 (26.9) | 9 (42.9) | 8 (40.0) | 6 (37.5) | 30 (35.7) |
| Smoking, n (%) | |||||
| Never | 6 (22.2) | 1 (4.8) | 1 (50.0) | 1 (6.3) | 9 (10.7) |
| Current or former | 21 (77.8) | 20 (95.2) | 19 (95.0) | 15 (93.8) | 75 (89.3) |
| Stage, n (%) | |||||
| IA3 | 4 (14.8) | 1 (4.8) | 6 (30.0) | 1 (6.3) | 12 (14.3) |
| IB | 7 (25.9) | 4 (19.0) | 2 (10.0) | 1 (6.3) | 14 (16.7) |
| IIA | 3 (11.1) | 4 (19.0) | 1 (5.0) | 2 (12.5) | 10 (11.9) |
| IIB | 11 (40.7) | 7 (33.3) | 8 (40.0) | 7 (43.8) | 33 (39.3) |
| IIIA | 2 (7.4) | 5 (23.8) | 3 (15.0) | 5 (31.3) | 15 (17.9) |
| Histology, n (%) | |||||
| Adenocarcinoma | 18 (66.7) | 14 (66.7) | 11 (55.0) | 8 (50.0) | 51 (60.7) |
| Squamous cell carcinoma | 9 (33.3) | 7 (33.3) | 6 (30.0) | 4 (25.0) | 26 (31.0) |
| Large cell carcinoma | 0 | 0 | 2 (10.0) | 1 (6.3) | 3 (3.6) |
| Adenosquamous carcinoma | 0 | 0 | 0 | 1 (6.3) | 1 |
| Platen epithelial carcinoma | 0 | 0 | 0 | 1 (6.3) | 1 |
| Not specified | 0 | 0 | 1 (5.0) | 1 (6.3) | 2 |
Abbreviations: Danva, danvatirsen; Durva, durvalumab; ECOG PS, Eastern Cooperative Oncology Group performance status; Mona, monalizumab; Ole, oleclumab.
aECOG PS was not available for one patient in the durvalumab monotherapy arm.